The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | The potential future implementation of Type II JAK inhibitors into the treatment landscape of MPNs
In this interview, Andrew Dunbar, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential future implementation of Type II JAK inhibitors into the treatment landscape of myeloproliferative neoplasms (MPNs), highlighting that these agents are still in early phase trials and that further data is needed to evaluate their value and side effect profiles. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, again, I think it’s very early to say for sure what the implications are for Type II JAK2 inhibitor agents only because these are very early Phase I, first-in-human clinical trials, and so I don’t think we have a full sense of how these drugs will do. And then in particular, we need to be monitoring for side effects, monitoring for the expected side effects, assessing for unexpected side effects, because in many respects, this really is a completely new class of JAK inhibitor...
So, again, I think it’s very early to say for sure what the implications are for Type II JAK2 inhibitor agents only because these are very early Phase I, first-in-human clinical trials, and so I don’t think we have a full sense of how these drugs will do. And then in particular, we need to be monitoring for side effects, monitoring for the expected side effects, assessing for unexpected side effects, because in many respects, this really is a completely new class of JAK inhibitor. So that’s one thing that we need to be mindful of. And then long term, I think if, again, there’s activity in this sort of Type I JAK inhibitor refractory setting, there’ll have to be, I think, bigger conversations in the MPN community about then where Type II inhibitors might fit, again, in an upfront setting, you know, in the landscape, knowing that, again, we already have several inhibitors, each with their specific clinical indications. So it’s an exciting time in that we have a lot of options. And so, again, a lot will be borne out as more of this data from the trial comes around.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Ajax Therapeutics.
